S-1/A: Hinge Health Files for IPO, Aiming to Revolutionize Musculoskeletal Care with AI-Powered Platform

Hinge Health, a technology platform focused on transforming musculoskeletal care, has filed an S-1/A form for its initial public offering, planning to list on the NYSE under the symbol HNGE.

Summary

• Hinge Health is preparing for its initial public offering, offering 8,522,528 shares of Class A common stock, with selling stockholders offering 5,143,472 shares.
• The company anticipates an initial public offering price between $28.00 and $32.00 per share and has been approved for listing on the New York Stock Exchange under the symbol HNGE.
• Following the offering, the holders of Class B common stock and Series E preferred stock will hold approximately 97.1% of the voting power.
• Hinge Health aims to transform musculoskeletal care using technology to scale and automate care delivery, reducing human care team hours by approximately 95% according to their estimates based on 2024 data.
• For the year ended December 31, 2024, Hinge Health reported revenue of $390.4 million, a 33% year-over-year increase, and a gross margin of 77%.
• Net cash from operating activities was $49.0 million, and free cash flow was $45.2 million for the year ended December 31, 2024.
• The company incurred a net loss of $11.9 million for the year ended December 31, 2024, but had net income of $17.1 million for the three months ended March 31, 2025.
• Hinge Health has over 2,250 clients, including 49% of Fortune 100 companies, and approximately 20 million contracted lives as of December 31, 2024.
• The company estimates the U.S. market for MSK medical costs at $661 billion in direct spend and $624 billion in indirect costs in 2023.
• Hinge Health intends to use substantially all of the net proceeds from this offering to satisfy tax withholding and remittance obligations related to the RSU Net Settlement.

Sentiment

Score: 7

Explanation: The document presents a balanced view, highlighting both the company's strengths and risks. The financial results show strong growth and improving profitability, but the company is still not consistently profitable. The company's innovative approach and large market opportunity are positive, but the competitive landscape and regulatory challenges are significant risks.

Positives

• Strong revenue growth of 33% year-over-year, reaching $390.4 million in 2024.
• High gross margin of 77% in 2024, indicating efficient operations.
• Positive net cash from operating activities and free cash flow in 2024.
• Large client base with significant penetration into Fortune 100 companies.
• High client retention rate of 98% as of December 31, 2024.
• AI-powered platform reduces human care team hours significantly.
• Expansion into new markets, including fully-insured and Medicare Advantage populations.
• Strong partner network, including major health plans and PBMs.

Negatives

• The company has a history of net losses, although it achieved net income for the three months ended March 31, 2025.
• High concentration of voting control among Class B shareholders and Series E preferred stockholders post-IPO.
• Reliance on a limited number of health plans and partners for a substantial portion of client relationships.
• The company faces intense competition in the digital health market.
• The company is subject to extensive government regulation in the healthcare industry.

Risks

• The company may not be able to achieve or maintain profitability.
• Failure to attract new clients or retain existing ones could adversely affect financial results.
• Reliance on AI and machine learning technologies exposes the company to development challenges and regulatory uncertainties.
• The company may be unable to protect its intellectual property.
• Healthcare reform measures may increase operating costs.
• The price of Class A common stock may be volatile.
• The dual class structure concentrates voting control.
• The company is an emerging growth company and may take advantage of reduced reporting requirements.

Future Outlook

Hinge Health plans to expand its client base, increase adoption across existing clients, launch new programs, and expand into new markets, including international expansion and government healthcare programs.

Industry Context

Hinge Health operates in the rapidly evolving digital health market, specifically targeting the large and costly musculoskeletal (MSK) conditions market. The company aims to disrupt traditional MSK care by offering a technology-driven, scalable, and personalized solution.

Comparison to Industry Standards

• Hinge Health competes with other digital MSK care providers like Kaia Health, Omada Health, Sword Health, and Vori Health.
• The company differentiates itself through its AI-powered platform, comprehensive care approach, and strong partner network.
• Hinge Health's 77% gross margin in 2024 compares favorably to traditional in-person physical therapy, which has significantly lower margins.
• The company's 117% net dollar retention rate indicates strong client satisfaction and recurring revenue, which is a key metric for SaaS-based healthcare companies.

Related Party Transactions

• The company has engaged in transactions with entities affiliated with its major stockholders, including Insight, Atomico, Coatue, Tiger Global, 11.2 Capital, and Bessemer.
• The company has entered into a stock repurchase agreement with Coatue to repurchase shares of Series E preferred stock for $50.0 million.
• The company has entered into a participation letter with Coatue, granting them the right to purchase up to 5% of the shares of Class A common stock in the IPO.
• The company has entered into indemnification agreements with its directors and executive officers.

Stakeholder Impact

• Shareholders: The IPO will provide liquidity for existing shareholders and create a public market for the company's stock.
• Employees: The company's success will depend on its ability to attract and retain talented employees.
• Customers: The company aims to provide cost-effective and accessible MSK care to its members.
• Suppliers: The company relies on third-party suppliers for its inventory, including the Enso device.
• Creditors: The company's financial performance will impact its ability to meet its debt obligations.

Next Steps

• The company will proceed with its initial public offering and listing on the New York Stock Exchange.
• Hinge Health will continue to expand its client base, increase adoption across existing clients, launch new programs, and expand into new markets.
• The company will focus on further developing its AI-powered platform and data integrations.

Key Dates

Keywords

Hinge Health, IPO, musculoskeletal care, digital health, AI, MSK, healthcare, technology, physical therapy, revenue, gross margin, contracted lives, members, Enso, TrueMotion